A

Azitra Inc
AMEX:AZTR

Watchlist Manager
Azitra Inc
AMEX:AZTR
Watchlist
Price: 0.2744 USD -4.06% Market Closed
Market Cap: $2.9m

Relative Value

The Relative Value of one AZTR stock under the Base Case scenario is hidden USD. Compared to the current market price of 0.2744 USD, Azitra Inc is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

AZTR Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

AZTR Competitors Multiples
Azitra Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Azitra Inc
AMEX:AZTR
3.1m USD 0 -0.5 -0.2 -0.2
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 746 422.5 -160 391.7 -165 649.1 -163 758.9
US
Abbvie Inc
NYSE:ABBV
389.3B USD 6.5 165.8 16.1 22.9
US
Amgen Inc
NASDAQ:AMGN
187.3B USD 5.2 26.7 19.1 19.1
US
Gilead Sciences Inc
NASDAQ:GILD
170.5B USD 5.9 21 14.2 14.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
121.2B USD 10.3 33 24.3 25.4
US
Epizyme Inc
F:EPE
94.1B EUR 2 087.6 -532.7 -682 -663.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.1B USD 5.6 17.5 16.7 18.9
AU
CSL Ltd
ASX:CSL
88.6B AUD 3.9 20.2 9.2 11.5
NL
argenx SE
XBRU:ARGX
43.4B EUR 14.2 33.3 67.4 69.2
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.4B USD 14.9 1 095.4 147.6 179
P/S Multiple
Revenue Growth P/S to Growth
US
A
Azitra Inc
AMEX:AZTR
Average P/S: 3 374 857.7
Not Available
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 746 422.5
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.5
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
5.2
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.9
4%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.3
10%
1
US
E
Epizyme Inc
F:EPE
2 087.6
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.6
6%
0.9
AU
CSL Ltd
ASX:CSL
3.9
5%
0.8
NL
argenx SE
XBRU:ARGX
14.2
49%
0.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
14.9
47%
0.3
P/E Multiple
Earnings Growth PEG
US
A
Azitra Inc
AMEX:AZTR
Average P/E: 176.6
Negative Multiple: -0.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 391.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
165.8
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
26.7
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
21
191%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
33
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -532.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.5
10%
1.8
AU
CSL Ltd
ASX:CSL
20.2
11%
1.8
NL
argenx SE
XBRU:ARGX
33.3
42%
0.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 095.4
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
A
Azitra Inc
AMEX:AZTR
Average EV/EBITDA: 39.3
Negative Multiple: -0.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -165 649.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.1
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
19.1
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
14.2
7%
2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.3
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -682 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.7
11%
1.5
AU
CSL Ltd
ASX:CSL
9.2
8%
1.2
NL
argenx SE
XBRU:ARGX
67.4
810%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
147.6
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
A
Azitra Inc
AMEX:AZTR
Average EV/EBIT: 45
Negative Multiple: -0.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -163 758.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.9
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
19.1
20%
1
US
Gilead Sciences Inc
NASDAQ:GILD
14.2
13%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.4
16%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -663.8 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.9
13%
1.5
AU
CSL Ltd
ASX:CSL
11.5
11%
1
NL
argenx SE
XBRU:ARGX
69.2
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
179
N/A N/A